BioPharmSignal logoBioPharmSignal

Biotech News

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

AtriCure (ATRC)AtriCureEarnings

MASON, Ohio --(BUSINESS WIRE)--Jan. 12, 2026-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the

Related news

ATRCAtriCure2026-07-23 20:01 EST

AtriCure Reports Second Quarter 2026 Financial Results

ATRCAtriCure2026-07-02 12:00 EST

AtriCure to Announce Second Quarter 2026 Financial Results

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

FEMYFEMASYS2026-08-14 20:05 EST

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

View all latest news

AtriCure

Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm. Ablation Technologies The Isolator Synergy Ablation...

Recent company news

ATRCAtriCure2026-07-27 12:00 EST

AtriCure to Participate at Upcoming Investor Conferences

ATRCAtriCure2026-07-23 20:01 EST

AtriCure Reports Second Quarter 2026 Financial Results

ATRCAtriCure2026-07-02 12:00 EST

AtriCure to Announce Second Quarter 2026 Financial Results

ATRCAtriCure2026-05-27 12:00 EST

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

ATRCAtriCure2026-05-05 20:01 EST

AtriCure Reports First Quarter 2026 Financial Results

Stock data

Close
48.98 USD
Market cap
1.31B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States